Resistance of herpesviruses to antiviral drugs: Clinical impacts and molecular mechanisms

Drug Resistance Updates

Volumn 5, Issue 2, 2002, Pages 88-114

  Gilbert, Christian ^a   Bestman Smith, Julie ^a   Boivin, Guy ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Antiviral drugs; Clinical impacts; Herpesviruses; Resistance

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; GANCICLOVIR; NUCLEOSIDE ANALOG; THYMIDINE KINASE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CYTOMEGALOVIRUS; DRUG MECHANISM; DRUG SENSITIVITY; GENOTYPE; HERPES SIMPLEX VIRUS; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; MUTATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION; ANIMAL; DRUG EFFECT; GENETICS; MULTIDRUG RESISTANCE; PHYSIOLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; MUTATION;

EID: 0036527281     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(02)00021-3     Document Type: Review

References (197)

1. Value of a new rapid non-radioactive sequencing method for analysis of the cytomegalovirus UL97 gene in ganciclovir-resistant strains
2. Differential susceptibility of several drug-resistant strains of herpes simplex virus type 2 to various antiviral compounds
3. Resistance of herpes simplex virus type against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene
4. Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase; comparison of secondary structure predictions and conservation
5. Four dually resistant human cytomegalovirus strains from AIDS patients: Single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively
6. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate
7. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS
8. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood
9. The Cys607 → Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients
10. Emergence of a ganciclovir-resistant human cytomegalovirus strain with a new UL97 mutation in an AIDS patient
11. Coinfection of the immunocompromised but not the immunocompetent host by multiple human cytomegalovirus strains
12. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system
13. Antiviral drugs
14. Failure of foscarnet in disseminated herpes zoster
15. A conserved 3′-5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases
16. Herpes simplex vires virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy
17. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues
18. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-l-(hydroxymethyl)ethoxy] methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus
19. A human cytomegalo-virus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate
20. A general structure for DNA-dependent DNA polymerases
21. Acyclovir-resistant bilateral keratitis associated with mutations in the HSV-1 thymidine kinase gene
22. Drug-resistant herpesviruses: Should we look for them?
23. Acyclovir susceptibilities of herpes simplex virus strains isolated from solid organ transplant recipients after acyclovir or ganciclovir prophylaxis
24. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis
25. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS
26. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease
27. A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: Longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments
28. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis
29. Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: A UK-based survey
30. Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus
31. Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy
32. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: Risk factors and prognostic significance
33. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses
34. Resistant herpes simplex virus type 1 infection: An emerging concern after allogeneic stem cell transplantation
35. Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug
36. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: Relationship to clinical outcome
37. Penciclovir-resistance mutations in the herpes simplex virus DNA polymerase gene
38. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir
39. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates
40. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance
41. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease
42. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from three subjects receiving prolonged antiviral therapy
43. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance
44. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance
45. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir
46. Foscarnet: A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocomproised patients with cytomegalovirus retinitis
47. Survey of resistance of herpes simplex virus to acyclovir in northwest England
48. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments
49. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture
50. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate
51. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir
52. Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir
53. Mechanism of action of foscarnet against viral polymerases
54. A cosmid-based system for constructing mutants of herpes simplex virus type 1
55. Evidence that the "active centre" of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide
56. Therapeutic potential of HPMPC as an antiviral drug
57. Resistance to antiviral inhibitors caused by the mutation S889A in the highly-conserved 885-GDTDS motif of the herpes simplex virus type 1 DNA polymerase
58. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection
59. Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients
60. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir
61. Foscaruet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation
62. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo
63. Homology between DNA polymerases of poxviruses, herpesviruses, and adenoviruses: Nucleotide sequence of the vaccinia virus DNA polymerase gene
64. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes
65. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
66. The dynamics of human cytomegalovirus replication in vivo
67. Herpes simplex virus resistant to acyclovir: A study in a tertiary care center
68. Resistance of human cytomegalovirus to antiviral drugs
69. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients
70. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients
71. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis
72. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome
73. Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant
74. Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene
75. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir
76. Foscarnet-resistant multidermatomal zoster in a patient with AIDS
77. Acyclovir-resistant varicella-zoster virus: Phenotypic and genetic characterization
78. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis
79. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine
80. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients
81. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay
82. Sequence and mapping analyses of the herpes simplex virus DNA polymerase gene predict a C-terminal substrate binding domain
83. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition
84. Polymerization activity of an alpha-like DNA polymerase requires a conserved 3′-5′ exonuclease active site
85. Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients
86. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following pre-emptive GCV therapy in allogenic stem cell transplant recipients
87. Rapid selection of a cytomegalovirus UL97 mutant in a heart transplant recipient on pre-emptive ganciclovir therapy
88. Aphidicolin resistance in herpes simplex virus type I reveals features of the DNA polymerase dNTP binding site
89. Antiviral agents
90. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains
91. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir
92. Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir
93. In vitro and in vivo characerization of herpes simplex virus clinical isolates recovered frompatients infected with human immunodeficiency virus
94. Intracellular metabolism of the antiherpes agent (S)-l-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine
95. Allele replacement: An application that permits rapid manipuation of herpes simplex virus type 1 genomes
96. An altered spectrum of herpes simplex virus mutations mediated by an antimutator DNA polymerase
97. A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance
98. Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity
99. Mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene can confer altered drug sensitivities
100. GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E
101. Cytomegalovirus retinitis and viral resistance: Prevalence of resistance at diagnosis, 1994
102. Cytomegalovirus retinitis and viral resistance: Ganciclovir resistance
103. Incidence of foscamet resistance and cidofovir resistance in patients treated for cytoegalovirus retinitis
104. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis
105. Biochemical studies on the herpes simplex virus-specified deoxypyrimidine kinase activity
106. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir
107. Comparison of human cytomegalovirus DNA polymerase activity for ganciclovir-resistant and -sensitive clinical strains
108. Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir
109. The herpes simplex virus type 1 DNA polymerase gene: Site of phosphonoacetic acid resistance mutation in strain Angelotti is highly conserved
110. Properties of herpes simplex virus DNA polymerase and characterization of its associated exonuclease activity
111. Brief report: Recurent acyclovir-resistant genital herpes in an immunocompetent patient
112. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation
113. Polymorhisms of thymidine kinase gene in herpes simplex virus type 1: Analyis of clinical isolates from herpetic keratitis patients and laboratory strains
114. Herpes simplex virus type 1 DNA polymerase: Mutational analysis of the 3′-5′ -exonuclease domain
115. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates
116. Related functional domains in virus DNA polymerases
117. Role of genotypic analysis of the thymidine kinase gene of herpes simplex virus for determination of neurovirulence and resistance to acyclovir
118. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
119. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving pre-emptive therapy
120. Human cytomegalovims UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir
121. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo
122. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents
123. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir
124. Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor
125. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing
126. Engineered herpes simplex virus DNA polymerase point mutants: The most highly conserved region shared among alpha-like DNA polymerases is involved in substrate recognition
127. Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates
128. In vitro mutagenesis of the herpes simplex virus type 1 DNA polymerase gene results in altered drug sensitivity of the enzyme
129. The structure and function of the HSV DNA replication proteins: Defining novel antiviral targets
130. A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents
131. Susceptibilities of human cytomegalovirus clinical isolates to bay38-4766, bay43-9695, and ganciclovir
132. Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy
133. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection: A multicenter double-blind trial
134. Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein
135. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir
136. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients
137. Reactivation of acyclovir-resistant thymidine kinase-deficient herpes simplex virus harbouring single base insertion within a 7 Gs homopolymer repeat of the thymidine kinase gene
138. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)
139. Rising pp65 antigenemia during pre-emptive anticytomegalovirus therapy after allogenei chematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes
140. Herpes simplex virus isolates from an immunocompromised patient who failed to respond to acyclovir treatement express thymidine kinase with altered substrate specificity
141. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: Report on a 2-year sensitivity screening survey
142. Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate
143. A point mutation in the thymidine kinase gene is responsible for acyclovir-resistance in herpes simplex virus type 2 sequential isolates
144. Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet
145. A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice
146. Acyclovir resistance in herpes simplex virus isolates from keratitis cases: An analysis from a developing country
147. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency
148. Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child
149. Purification and photoaffinity labeling of herpes simplex virus type-1 thymidine kinase
150. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients
151. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation
152. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis
153. Progressive esophagitis from acyclovir-resistant herpes simplex: Clinical roles for DNA polymerase mutants and viral heterogeneity?
154. Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: Preliminary data
155. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection
156. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome
157. Foscamet-resistant herpes simplex virus infection in patients with AIDS
158. A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frame
159. Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: Evidence for reactivation of acyclovir-resistant herpes simplex virus
160. Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome
161. Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients
162. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir
163. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: Masked heterogeneity or reversion?
164. Homopolymer mutaional hot spots mediate herpes simplex virus resistance to acyclovir
165. Molecular analysis of the pyrimidine deoxyibonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus
166. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapysequentially failed
167. Cytomegalovirus ventriuloencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: Clinical and molecular evidence of drug resistance
168. The 3prime;-5prime; exonuclease activity located in the DNA polymerase delta subunit of Saccharomyces cerevisiae is required for accurate replication
169. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients
170. Polyradiulopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: Phenotypic and genotypic characterization of sequential virus isolates
171. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes
172. A new topical treatment for resistant herpes simplex infections
173. Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens
174. Ganciclovir-resistant cytomegalovirus clinical isolates: Mode of resistance to ganciclovir
175. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells
176. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives
177. Chronic vulvar ulceration in an immunocompetent woman due to acyclovir-resistant, thymidine kinase-deficient herpes simplex virus
178. Antiviral agents and susceptibility tests
179. Improved DNA hybridization method for detection of acylovir-resistant herpes simplex virus
180. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS
181. Acyclovir is phoshorylated by the human cytomegalovirus UL97 protein
182. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity
183. A gancicloviresistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors
184. Latency-associated transcript but not reactivatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1
185. A single-base change within the DNA polymerase locus of herpes simplex virus type 2 can confer resistance to aphidicolin
186. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS
187. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscamet and slow growth phenotype
188. Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: A double-blind trial
189. Acyclovir: A decade later
190. Replication, latent infection, and reactivation in neuronal culture with a herpes simplex virus thymidine kinase-negative mutant
191. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma
192. Detection of human cytomegaovirus mutations associated with ganciclovir resistance in cererospinal fluid of AIDS patients with central nervous system disease
193. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency
194. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation
195. Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency
196. Human DNA polymerase alpha gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases
197. Primary structure of the catalytic subunit of calf thymus DNA polymerase delta: Sequence similarities with other DNA polymerases